In Memoriam: Robert Jennejahn (1951–2023)
It is with a heavy heart that we announce the passing of Robert Jennejahn, a valued contributor to Vein Therapy News. His association with our book spanned several issues, during which he made significant contributions. On the 7th of October this year, Robert passed on at the age of 71.
Has your practice seen an increase in blood clots since the COVID vaccines became available?
We would like to hear from you! Please call Gary Pittman Jr at 512-637-0373 or email garypjr@pcinews.com.
Janssen’s Xarelto studied for secondary prevention of VTE in cancer patients
The Janssen Pharmaceutical Companies of Johnson & Johnson recently announced observational data from 8 years of clinical practice showing that the company’s oral Factor Xa inhibitor Xarelto (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a
Stryker’s Target Tetra detachable coil for treating small aneurysms cleared by FDA
Stryker announced FDA 510(k) clearance of the Target Tetra detachable coil, the latest addition to the company’s Target platform. The Target Tetra device, which is specifically designed to treat small aneurysms, combines a new tetrahedral shape and softness level. According to the company, the delicate nature of small aneurysms makes
Corindus rebranded as Siemens Healthineers Endovascular Robotics
Corindus, a Siemens Healthineers Company, announced it has been rebranded to Siemens Healthineers Endovascular Robotics, a dedicated business within the Advanced Therapies area of Siemens Healthineers. The aim of the Endovascular Robotics business is to advance interventions with robotics and change the way that care is delivered through innovations that
Cook Medical Appoints John A. Kaufman as Chief Medical Officer
Cook Medical announced the appointment of John A. Kaufman, MD, MS, as Chief Medical Officer (CMO), effective July 2023. Currently, Dr. Kaufman is the inaugural Chair of the Dotter Department of Interventional Radiology, Director of the Dotter Interventional Institute, and Frederick S. Keller Professor of Interventional Radiology at the Oregon
Merit Medical’s EmboCube Embolization Gelatin to Be Studied to Control Bleeding or Hemorrhage
Merit Medical Systems, Inc. announced the enrollment of the first patient in the company’s prospective, observational study of EmboCube embolization gelatin to control bleeding or hemorrhage. The EmboCube Embolization Gelatin study is designed to enroll 100 patients across multiple centers in Australia and France. The company advised that EmboCube is
Vesalio’s NeVa Thrombectomy Device First-Pass Rates Evaluated in Published Study
Vesalio announced that data on the use of the company’s NeVa thrombectomy device were published by Arsida Bajrami, MD, et al in Interventional Neuroradiology. The company stated that the NeVa platform is designed to consistently achieve first-pass recanalization in stroke by effectively removing all types of neurovascular clots from a
FDA Breakthrough Device designation
Cook Medical announced that its Thoraco+ endovascular system has received Breakthrough Device designation from the FDA. The company describes Thoraco+ as a next- generation, off-the-shelf device in the Zenith platform, indicated for patients with thoracoabdominal aortic aneurysms (Crawford classification I-IV). It has four side branches for the celiac, superior mesenteric,
Alucent’s natural vascular scaffolding to be evaluated in ACTIVATE II FIH trial
Alucent Biomedical Inc. announced that it has enrolled the first patient in ACTIVATE II, an Australia-based first-in-human clinical trial to evaluate the safety and efficacy of AlucentNVS, the company’s natural vascular scaffolding device. According to the company, the ACTIVATE II trial will enroll up to 50 patients at up to